NCT03646357

Phase 4Interventional

Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.

View on ClinicalTrials.gov ↗

Timeline

Start date: Oct 1, 2018
Primary completion: Oct 1, 2022
Completion date: Oct 1, 2023
First posted: Aug 24, 2018
Last posted: Oct 2, 2018
Enrollment: 10000
Arms / groups: 2 / —
Source: AACT · ctgov ingestion

Sponsors

University of OsloLead sponsor
Drammen sykehusCollaborator
University of BergenCollaborator
University of StavangerCollaborator
University of OsloReponsible party - principal investigator
University of OsloStudy chair
Sorlandet Hospital HFCollaborator
Norwegian University of Science and TechnologyCollaborator
The Hospital of VestfoldCollaborator
University Hospital of North NorwayCollaborator
University of OsloCollaborator
Nordland HospitalCollaborator
Diakonhjemmet HospitalCollaborator
South-Eastern Norway Regional Health AuthorityCollaborator
Sykehuset Innlandet HFCollaborator
University of OsloOfficial
Vestre Viken Ringerike SykehusCollaborator
Lovisenberg Diakonale HospitalCollaborator
University of OsloSponsor investigator

Drugs studied

carvedilol

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.